Loading
A phase 2 trial of BEBT-109 Capsule in non-small-cell lung cancer, run by BeBetter Med Inc, now recruiting.
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT06706713 by BeBetter Med Inc, with 200 participants planned, started 2022-04-15 and due to reach its primary completion in 2025-12-31. Interventions recorded: BEBT-109 Capsule.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares BeBetter Med and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/